Lynn Ing

Accomplished litigator protects life-sciences and chemical patents

Recognized as a “Rising Star,” Lynn’s deep patent litigation and prosecution experience is bolstered by her strong scientific expertise and background in cancer research. Among her many accomplishments, Lynn held an integral role in the successful appeal to the Supreme Court of Canada in AstraZeneca v Apotex, 2017 SCC 36, leading to the abolishment of the “promise doctrine” of patent utility in Canada.

With more than a decade of patent expertise, Lynn focuses on patent litigation and prosecution. In her prosecution practice, Lynn advises clients on biotechnology, chemical and pharmaceutical patent applications including for biologics. Her litigation practice and experience includes patent infringement, impeachment and damages actions and pharmaceutical litigation under the Patented Medicines (Notice of Compliance) Regulations. She has assisted clients in proceedings before the Ontario Superior Court of Justice, Ontario Court of Appeal, Federal Court, Federal Court of Appeal, and Supreme Court of Canada.

Research experience

Prior to her career in patent law, Lynn worked as a postdoctoral research fellow under Dr. Bob Kerbel, in collaboration with an early stage Canadian pharmaceutical company, in the area of tumour angiogenesis and innovative cancer therapies. Her graduate work was in the field of cell signaling and published in Oncogene and EMBO.

Lynn shares her expertise as a frequent contributor to Rx IP Update, the firm’s monthly newsletter on developments in Canadian intellectual property law and practice relating to the pharmaceutical industry.